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Complement membrane attack (MAC) in idiopathic LgA-glomerulone-
phritis. Antigens of the membrane attack complex of complement
(MAC), such as C5, C6, C9 and MAC-related neoantigen(s), were
demonstrated in the mesangium of 23 cases with IgA-glomerulonephri-
tis (lgA-GN) and two cases with Henoch—Schdnlein purpura nephritis
(HSP). High specificity of the polyclonal antibodies was verified by
dot—blot analysis. Control specimens lacking immunoglobulin deposits
were negative for MAC-related antigens. Markers of classical pathway
activation (Clq and C4) were observed only in two of 24 and one of 23
cases of lgA-GN and HSP, respectively. Glomerular distribution pat-
terns (mesangial vs. mesangio-peripheral) of immunoglobulin or com-
plement deposits were correlated for IgA and C3b/iC3b (P < 0.002), for
IgA and properdin (P < 0.002) and for IgA and MAC neoantigens (P <
0.01). Double immunostaining experiments revealed co-localization of
IgA and MAC neoantigens at identical mesangial and capillary sites.
Glomerular distribution of the less pronounced IgG or 1gM deposits did
not correlate with that of any complement—derived antigen. The pattern
of MAC-related antigens was found to be uniformly either mesangial or
mesangio-peripheral. Staining for MAC-related antigens was less in-
tense in IgA-GN cases with minimal glomerular lesions than in cases
with more advanced non-sclerosing lesions. IgA, C3d, and MAC
localized in corresponding glomerular sites. This is consistent with
complete local activation of complement by glomerular IgA deposits via
the alternative pathway. The possibility exists that MAC plays a
pathogenetic role, such as by irritation of bystander cells, in IGA-GN
and HSP.
igA mesangial glomerulonephritis (IgA-GN) is the most fre-
quent form of glomerulonephritis. The characteristic im-
munopathological findings, mesangial or mesangio-peripheral
granular deposits of IgA with or without concomitant IgG and
1gM deposits, were first described by Berger and Hinglais in
1968 [1] and later confirmed by many investigators [2—4].
Similar histopathological features are observed in Henoch—
Schönlein purpura nephritis (HSP) [5]. Although much effort
has been invested to clarify the pathomechanisms involved,
little information with respect to pathogenesis is available, it
has not been clarified whether deposits derive from soluble
immune complexes (IC), consisting of igA and unknown anti-
gens, such as from the gastrointestinal tract, or whether they
represent IgA polymers or oligomers containing no antigen. IgA
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polymers or IgA-IC have been detected in the serum of patients
with IgA-GN or HSP at least in the early stages of the disease
[6—12]. However, the factors causing IgA-IC or IgA aggregates
to be trapped within the mesangial area remain to be elucidated.
Finally, the events by which local deposition of IgA leads to
recurrent hematuria, glomerular lesions and progressive renal
failure are still unclear. One potential system mediating local
tissue damage is the complement system. Its involvement in
IgA-GN is suggested by the simultaneous occurence of granular
C3b deposits with mesangial IgA (and IgO or 1gM) deposits on
immunofluorescence (IF) [2—4]. Such local mesangial comple-
ment activation may cause tissue damage by one of these
possibilities (or their combination): local release of the potent
anaphylatoxic factors C4a, C3a, C5a, which trigger acute in-
flammatory responses via cellular (polymorphonuclear leuco-
cytes, thrombocytes or monocytes) and other mechanisms and
of which C5a has potent chemotactic activity, and formation of
the cytolytic membrane attack complex of complement (MAC),
which could directly destroy or irritate bystander cells in the
vicinity of the activation site or modify polyanion charge of
glomerular basement membrane.
Since accumulation of PMNs or monocytes is not regularly
detected in IgA-GN even during hematuric episodes, a patho-
genic role for C-derived anaphylatoxins is less probable. This
focused attention on the second possibility, the involvement of
the membrane attack complex. Therefore, the present study
was carried out to address the following questions: I) Can MAC
deposits be detected in glomeruli of patients with IgA-related
glomerulonephritis (idiopathic lgA-GN or HSP)? 2) Are IgA
and MAC localized in the same glomerular sites? 3) Is the
pattern and the amount of MAC deposits, as assessed semi-
quantitatively by indirect immunofluorescence, correlated with
histopathological features or with clinical findings (such as
hematuria and/or proteinuria) at the time of biopsy?
Immunohistological identification of MAC was based on the
demonstration of C5, C6, C9 by their respective antibodies and,
in addition, by an antiserum specific for neoantigen(s) present
on MAC but not on its single components C5, C6, C7, C8 and
C9. MAC neoantigens are exposed upon the assembly of the
late complement components with the formation of MAC [13].
Such antiserum against MAC-neoantigens is an elegant probe to
demonstrate complement activation involving the terminal
steps of the cascade.
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The results of this study indicate complete in situ activation
of the complement system in IgA-related glomerulonephritis.
Methods
Patients and biopsy material
Kidney biopsy specimens sent to the Institute of Immunol-
ogy, Heidelberg, between 1975 and 1980 and classified as
IgA-GN or HSP were evaluated in this retrospective study. All
specimens had been snap—frozen immediately after biopsy,
embedded in Tissue Tec (Miles Laboratories, Naperville, Illi-
nois, USA) in isopentane, cooled to its freezing point by liquid
nitrogen, and stored at —85°C until used in the present study.
The diagnosis of IgA-GN and HSP, respectively, was based on
the demonstration of deposits of IgA (with or without IgG, 1gM
and C3) in the mesangial area of the glomeruli by immunofluo-
rescence (IF) microscopy in the absence of liver disease or
SLE. Clinical features were compatible with the diagnosis in all
cases (Table 1). Biopsies without immunohistological findings
on routine examination served as controls. These patients had
been biopsied because of clinical signs suggesting glomerular
disease, but had no glomerular deposits on immunofluoresc-
ence.
A total number of 29 cases were re-examined. The clinical
features at presentation, selected clinical data at time of biopsy
and the results of the histopathological evaluation are summa-
rized in Table I.
Antisera
Rabbit anti-human IgG/FITC, anti-human IgA/FITC, anti-
human IgM/FITC, anti-human fibrinogen/FITC, anti-human
Clq/FITC, anti-human C4/FITC, anti-human C3c/FITC, unla-
beled anti-human C9 and anti-human S-protein were obtained
from Behringwerke (Marburg, FRG). Rabbit anti-human fibro-
nectin was purchased from Cappel Laboratories (Conchran-
ville, Pennsylvania, USA). Unlabeled rabbit anti-human C5 and
anti-human C3d/FITC were obtained from Dakopatts (Copen-
hagen, Denmark) and goat anti-human factor B/FITC, anti-
human factor H/FITC, anti-human factor P/FITC from Atlantic
Antibodies (Scarborough, New York, USA). Anti-rabbit C6
cross—reacting with human C6 was raised in C6 defective
rabbits as described [14]. Anti-C3d/FITC was affinity purified
using C3d bound to thiol sepharose according to Ross et a! [15].
Using C3b and C3d coated sepharose beads, the titers of
anti-human C3b and anti-human C3d as evaluated by serial
dilution were similar after appropriate adjustment, and yielded
comparable sensitivity of IF. Specificity of anti-human C3c was
verified by showing no cross—reaction with C3d coated beads,
whereas anti-human C3d gave a faint reaction with C3b and an
intensive one with C3d-coated beads.
Specificity of anti-CS, anti-C6 and anti-C9 was verified by
dot—blot analysis using purified components and by SDS-PAGE
immunoblotting using purified components and plasma as anti-
gen. All three antisera showed only minimal contaminating
antibodies against those other than the stated antigen with the
latter technique (which in our laboratory had a higher sensitiv-
ity than IF).
In indirect immunofluorescence (IF) tests with unlabeled
primary antibodies, swine anti-rabbit IgG/FITC from Dakopatts
or rabbit anti-goat IgG/FITC were used at a dilution of 1:10.
Normal rabbit IgG/FITC or normal goat IgG/FITC showed no
staining when used as controls for direct IF. Similarly, when the
primary antibody was omitted, FITC labeled secondary anti-
bodies failed to stain.
Antibodies against neoantigens present on the membrane
attack complex of complement (anti-MAC-neo) were produced
in rabbits as described previously [161.
Reactivity of the anti-MAC-neo was examined by several
independent techniques.
First, intermediate gel crossed immunoelectrophoresis tech-
nique was applied. Using yeast or zymosan activated NHS as
antigen, one precipitation arc appeared, which moved down
into the intermediate gel when anti-C5 and anti-C9 were pres-
ent; no precipitation occurred there with fresh human serum.
This indicates that the complexes precipitated by anti-MAC
carry also CS and C9 epitopes.
Second, when immunoferritin staining with cells bearing
various C5-9 intermediates was examined, such as EC5b67,
EC5b678, and EC5b6789, our anti-MAC-neo mainly reacted
with neoantigens present on the C5-8 part of MAC [17].
Complement lysed erythrocyte membranes incubated with anti-
MAC-neo and ferritin—labeled secondary antibodies revealed
(after negative staining) a high association of the ferritin label to
the complement lesions [16].
Third, no reactivity of anti-MAC-neo with plasma proteins,
yeast—activated serum proteins or purified MAC was found
when using SDS-PAGE immunoblotting technique. We inter-
pret this as evidence that anti-MAC-neo recognized epitopes
requiring specific protein conformations which are lost on
SDS-PAGE.
Fourth, selective specificity for MAC was proven using
dot—blot analysis: from complement activated serum, SCSb-9
complexes were separated from uncomplexed components by
gelfiltration on SuperoseTM 6 column (FPLC, Pharmacia Diag-
nostics, Uppsala, Sweden). As controls, fresh human sera
(NHS) were subjected to gelfiltration under identical condi-
tions. In the fractions collected, reactivity with anti-MAC,
anti-CS, anti-C9, anti-IgM, anti-IgG and anti-albumin was mea-
sured by dot—blot analysis. Antigenic activities of CS and C9
were found as one peak each in the late inclusion volume of
NHS. Anti-MAC-neo did not react with fractions of NHS. With
activated serum an additional antigenic activity of CS and C9
appeared in the void volume (and fractions following thereafter
in the early inclusion volume but distinct from the respective
peaks of free CS and C9). Such additional antigenic action of CS
and C9 coincided with anti-MAC-neo reactivity. We conclude
that the antibodies are directed against neoantigens present
only on the C5b-9 complex.
Fifth, anti-MAC-neo reacted with SCSb-9 isolated by ammo-
nium sulfate precipitation, gel filtration, and FPLC mono-Q
ion—exchange chromatography (purity proven by SDS—PAGE)
in dot—blot analysis even in the presence of human plasma or
polyclonal F(ab)2-fragments of rabbit anti-S protein in excess.
Sixth, absorption of anti-MAC-neo with purified SC5b-9
complexes completely abrogated the reactivity with MAC-
positive kidney biopsy specimen.
The IgG fraction of the anti-MAC-neo was prepared by ion
exchange chromatography [18] and used for indirect staining.
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Table 1. Clinical features of 23 patients with IgA-gomeru lonephritis, 2 patients with Henoch—SchOnlein purpura and 4 control patients
Age at Course
At time of biopsy
Blood Serum
Patient onset! Age at
no. sex biopsy Presenting symptomsa
before
biopsyb
Urinary
proteinc
pressure creatinine
mm Hg mg%
Histopathological
feature
IgA-glomerulonephritis
SF 6 gross hematuria IM no 110/70 0.5 MGL
2 56M 56 microhematuria IMX no 140/80 3.0c FSGN
3 37M 39 microhematuria, IM no 140/95 l.6C MGL
hypertension
4 19M 20 proteinuria IM >lg/day 1801100d 0.8 FSGN
5 12M 13 gross hematuria IM <lglday* 120/70 0.9 FSGN
6 18M 20 microhematuria IX <Ig/day 130/80 0.8 MGL
7 36M 37 gross hematuria, IMX no 120/80 0.8 MGN
proteinuria
8 30M 31 hypertension ND <Ig/day 160/110" l.7C OS
9 23M 29 proteinuria, PPM <Ig/day 130/70 1.1 MGN
microhematuria
10 9M 15 gross hematuria IMX no 125/80 0.7 FSGN
11 9M 11 edema, gross hematuria PM <Ig/day 130/90 0.7 EEGN
12 1IM 12 microhematuria, PM no 125/80 0.7 MGL
proteinuria
13 33F 33 gross hematuria IMX no 110/80 0.9 MGL
14 22F 23 gross hematuria IM <Ig/day 140/80 0.7 MGL
15 28M 29 microhematuria
16 45M 46 gross hematuria
IMX
IMX
<Ig/day
>Ig/day
110/70 1.2
210/130" l.9C
MON
MON
17 9M II gross hematuria IMX no 120/90 0.7 FSGN
18 9M 12 gross hematuria
19 40M 48 hypertension,
1PM
IMX
>Ig/day
>Ig/day
130/90 0.7
170/110" 1.0
EEGN
MGN
gross hematuria
20 23M 41 microhematuria IM <Ig/day 135/90 1.3 MON
21 15M 15 microhematuria PM <Ig/day 140/70 0.8 MGL
22 18M 19 proteinuria, IMX <Ig/day 130/90 1.2 MGN
microhematuria
23 29F 33 proteinuria PPM >lg/day 130/85 I.4C MGN
Henoch—Schönlein purpura nephritis
24 9M 9 purpura 1PM no 120/70 0.8 FSGN
25 8F 10 purpura PMX no 120/80 0.4 MON
Controls: immunohistologically negative cases
26 4M 5 proteinuria
27 37M 37 gross hematuria
PPM
ARF
<Ig/day
<Ig/day
140/90 0.7
170/120" 2.I''
MGL
MON
28 31M 31 edema ARF <Ig/day 140/90 5.9" MON
29 6F 10 gross hematuria IM <Ig/day 110/60 0.7 MGL
a First symptoms: hypertension, blood pressure >140/90 mm Hg: gross hematuria, >10.000 RBC/pi; microhematuria, microscopic hematuria;
proteinuria, >150 mg/day
b Abbreviations are: IM, intermittent microscopic hematuria; IX, intermittent macroscopic hematuria; IMX, intermittent microscopic and gross
hematuria; 1PM, intermittent proteinuria and microscopic hematuna; PM, persistent microscopic hematuria; PPM, persistent proteinuria and
microscopic hematuria; PMX, persistent microscopic hematuria with macroscopic episodes; ND, no data available
Proteinuria, *hjgher in the course before biopsy; no <150 mg protein/I .73 square meter/day; <lg/day 150 — 1000 mg protein/day (for children
normalized/i .73 square meter/day); > Ig/day more than Ig protein/day (for children normalized/I .73 square meter/day)
d Elevated, >140/90 mm Hg
"Above 1.3 mg% in adults or above range for sex and age matched controls given by Goldsmith [28]
Abbreviations are: MGL, minimal glomerular lesions; FSGN, focal and segmental glomerulonephritis; MGN, mesangial proliferative
glomenilonephritis; EEGN, endo- and extracapillary proliferative glomerulonephritis; OS, diffuse glomerulosclerosis
Immunofluorescence microscopy
Cryostat sections (4 m) of specimens were fixed for 10
minutes in acetone, air dried, and incubated with the respective
FITC-labeled antibodies diluted 1:20 in PBS (except anti-
fibronectin 1:5) or with unlabeled antibodies diluted 1:10 (ex-
cept: anti-MAC-neo undiluted). After incubation and washing
steps according to the routine protocol for IF [19] the sections
were mounted in PBS-glycerol. In case of unlabeled first
antibodies the appropriate FITC-labeled second antibodies
were used. Secondary antibodies failed to react with human
tissue in control sections.
Specimen sections with at least one glomerulus (range I to 40,
mean 7) were examined in a Zeiss Standard 18 fluorescence
microscope equipped with a vertical epi-illuminator (lamp:
HBO 50; excitation filter 485 + 10 nm; barrier filter 515 nm)
(Zeiss, Oberkochen, FRG). The immunohistological (IF) find-
ings in each specimen were assessed and scored with respect to
the following criteria by two independent observers who were
unaware of the diagnosis: (a) total number of glomeruli; (b)
number of affected glomeruli; (c) localization of glomerular
deposits, that is, deposits along the glomerular basement mem-
brane (peripheral), purely mesangial (mesangial), mainly
mesangial with additional spreading into the peripheral base-
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ment membrane (mesangio-peripheral); (d) size of mean depos-
its (fine, intermediate or coarse granular); (e) overall fluores-
cence intensity of the deposits per glomerulus; that is, weak
(1+), or marked (2+) or extensive (3+).
The estimated scores (1+, 2+, or 3+) were taken to calculate
the sum of the scores for C5, C6, C9 and MAC neoantigens
staining (Table 2). Photomicrographs from at least one repre-
sentative glomerulus per antibody and per section were taken at
a magnification of 125x and at constant exposure time (32 sec)
using Kodak Ektachrom 400 ASA films (Eastman Kodak,
Rochester, New York, USA).
In experiments to examine whether IgA and MAC are depos-
ited in the same glomerular site, one glomerular section was
simultaneously examined with anti-MAC-neo and IgA antibod-
ies. First, sections were incubated with F(ab)2-fragments/FITC
of goat-anti-human IgA (Jackson Dianova, Hamburg, FRG)
followed by rabbit-anti-MAC-neo and alkaline—phosphatase
(AP)-labeled F(ab)2 fragments of goat-anti-rabbit IgG. Omission
of anti-MAC-neo gave negative AP staining results. Further
experiments were done using in the second—step mouse mono-
clonal antibodies against the C9a fragment of C9 obtained by
alpha—thrombin cleavage (Dr. Kroll, Bayer Co., Leverkusen) or
monoclonal antibody against C5b neoantigen non-reactive with
native CS (20; unpublished material). For these two antibodies
the APAAP technique [21] was used.
Statistics
In cases where all four stainings could be performed (N =
16), the sum of the scores for CS, C6, C9 and MAC neoantigens
were used to correlate the amount of MAC with the histopath-
ological features and clinical findings, that is, proteinuria
(no/yes) or renal function (serum creatinine) by the rank sum
test (Wilcoxon).
The relations between IF findings and histopathological le-
sions or clinical features were examined using chi—square tests.
A conservative level of P < 0.02 was chosen as cut—off level for
statistical significance.
Results
Immuno globulin deposits in IgA-glomerulonephritis
The immunohistological findings are summarized in Table 2.
By definition, in all biopsy specimens from patients with
IgA-glomerulonephritis, IgA was the predominant immunoglob-
ulin class diffusely deposited in the mesangial area of the
glomeruli. The pattern of IgA deposition varied between purely
mesangial (m, 14 of 23 cases) and mesangio-peripheral (mp, 9 of
23 cases); the latter is illustrated in Figure 1.
Additional IgG and/or 1gM deposits of lower intensity were
observed in all 23 patients (Table 2).
Deposits of complement factors in IgA glomerulonephritis
C4-related antigens and/or Clq (markers of classical pathway
activation) were observed in only one of 21 and two of 22 cases
of IgA-GN in whom these staining could be performed (whereas
in our experience these deposits are found in 40 to 60, and 80 to
90%, respectively, of patients with lupus nephritis).
Activation of the alternative pathway was suggested in 22 of
23 cases by mesangial deposition of factor P. In eight of 22
cases, in addition, factor H was present in the deposits. Factor
B was observed in one of2l cases only. Furthermore, C3b/iC3b
(C3c-related antigen) was observed in all cases of IgA-GN and
with marked or striking intensity in 20 of 23 specimens.
Glomeruli of all patients stained intensely with anti-C3d in a
granular pattern. A mesangio-peripheral pattern of deposition
was observed in 16 of 23 cases. Elution experiments performed
with six biopsies, using either I M propionic acid or 3 M thio-
cyanate (for 30 mm at room temperature and post-treatment
with inactivated fetal calf serum to suppress non-specific bind-
ing) revealed virtually no loss of C3d. This finding suggests
covalent binding of C3d.
Activation of the complete complement cascade with depo-
sition of MAC in the mesangium (as revealed by anti-MAC
neoantigens; representative examples given in Fig. 2—4) was
noted in 18 of 18 cases with sufficient number of glomeruli. CS,
C6 and C9 reactivity of the deposits with mesangial or
mesangio-peripheral pattern was found in 19 of 19, 19 of 21 and
18 of 19 cases, respectively. Staining with anti-MAC-neo re-
vealed the highest number of marked (2+) and striking (3+)
granular deposits (16 of 18), followed by anti-C5 (16 of 19),
anti-C9 (13 of 19) and anti-C6 (15 of 21). In seven cases,
experiments were performed to examine whether MAC-neo and
S-protein were co-localized at corresponding sites by staining
with anti-MAC-neo and anti-S-protein in sequential sections. In
all seven cases, the deposits virtually always stained with both
anti-MAC-neo and anti-S-protein.
In four representative cases, individual sections were simul-
taneously examined for glomerular IgA and MAC-neo-deposits,
using three different staining techniques as described in mate-
rials and methods. Figure 4 shows that the pattern of IgA
staining is superimposable upon that of MAC-neo staining and
that of C5b neoantigens staining (using monoclonal antibodies;
data not shown). This observation suggests co-localization of
immunoglobulin and complement deposits. Similar co—localiza-
tion was observed for MAC and C3d.
Immuno globulin and complement deposits in HSP
The two specimens from patients with HSP revealed quite
similar immunohistological features as observed in IgA-GN
(Table 2).
Deposits of antigens of the coagulation system
Fibrin deposits with mesangial or mesangio-peripheral distri-
bution were noted in 15 of 23 cases of IgA-GN. Additionally, in
four of 23 IgA-GN cases a peripheral pattern was noted. All 8 of
8 children examined, but only 11 of 15 adults with IgA-GN
examined had fibrin deposits in the glomeruli. The two HSP
biopsy specimens of children showed extensive mesangio-
peripheral fibrin deposits. Staining of kidney biopsy specimens
with FITC-labeled antibodies against fibronectin revealed a
purely mesangial pattern in 15 of 29 biopsy specimens and a
mesangio-peripheral pattern (Fig. 5) In 9 of 29 biopsies. Staining
with anti-fibronectin of four kidney biopsy specimens with no
immunohistologically—detectable immunoglobulin or comple-
ment deposits (used as controls) revealed purely mesangial
deposition of fibronectin without capillary involvement.
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Table 2. IF-findings in the glorneruli
Case Fibro-
no. IgA lgG 1gM Fibrin nectin Clq C4 C3b
IgA-glomerulonephritis
3+/rn 2+/rnp 1+/rn 3+/rn 3+/rn 0 0 1+/rn
2 3+/rn 0 l+/rnp 0 3+/rn 0 0 2+/rn
3 3+/rnp l+/rnp I+/rnp 3+/mp 3+/rn 0 0 2+/rn
4 3+/rn 2+/rn 0 3+/rn ND 0 0 2+/rn
5 3+/mp 1+/p 0 2+/rnp 3+/rnp 0 0 3+/rnp
6 3+/rn 1+/rn I+/rnp 2+/rnp 3+/rn 1+/rn 0 2+/rn
7 3+/rnp 2+/rnp I+/rnp 3+/rnp 3+/mp 0 0 2+/mp
8 3+/rn NDC 2+/rn 1+/p 3+/rnp 0 0 3+/rn
9 3+/rn 0 1+/rn 0 3+/rn 0 0 3+/rn
10 3+/mp 2+/rnp I+/rnp 3+/mp ND 0 NDC 3+/rn
11 3+/rn 2+/rn 1+/rn 1+/p 3+/rn 2+/rn 1+/rn 3+/rn
12 3+/rn 1+/p 0 3+/rn ND 0 0 1+/rn
13 3+/rnp 1+/p" 0 2+/p NDC 0 0 2+/rn
14 3+/rnp 2+/p l+/mp 0 3+/rnp 0 0 2+/rn
15 3+/rn 2+/p 0 2+/rn 2+/rn 0 0 2+/rn
16 3+/rn 1+/ph 0 0 NDC ND ND 3+/rn
17 3+/mp 1+/pb
18 3+/mp 1+/p"
1+/p
l+/mp
3+/rnp
3+/rnp
3+/mp
3+/mp
0
0
0
0
3+/mp
2+/mp
19 3+/rn 1+/pt 0 2+/rnp 3+/rnp 0 0 2+/rn
20 3+/rn 2+/rn
21 3+/rn 1+/p"
1+/rn
0
2+/p
3+/rn
3+/rn
2+/rn
0
0
0
0
3+/rn
1+/rn
22 3+/rnp 2+/p" 0 3+/rn 3+/rn 0 0 2+/rn
23 3+/rn 0 1+/rn 3+/rn 3+/rn 0 0 2+/rn
Henoch—Schän!ein purpura nephritis
24 3+/rnp 2+/pt I+/rnp 3+/rnp 3+/mp 0 0 3+/mp
25 3+/rnp 2/pt l+/rnp 3+/rnp 3+/rnp 0 0 l+/rnp
Controls
26 0 0 0 0 1+/rn 0 0 0
27 0 0 0 0 2+/rn 0 0 0
28 0 0 0 0 2+/rn 0 0 0
29 (1 0 0 0 2+/rn 0 0 0
Intensity of IF-staining: 0, no deposits detectable by IF; 1+, faint or weak granular deposits; 2+, rnarked granular deposits; 3+, extensive
granular deposits. Pattern of glomerular deposition: rn, exclusively rnesangial pattern of granular deposits; mp, mainly rnesangial granular deposits
with involvement of capillary loops; p. exclusively peripheral granular depositsb Pseudo-linear appearance of confluent granular peripheral deposits.
No glorneruli in the cryostat section
d Sum of individual scores (arbitrary units) for CS + C6 + C9 + MAC neoantigen irrespective of pattern
Statistical evaluations
In order to increase reproducibility of scoring of fluorescence
patterns and intensities, the following techniques were applied:
code number identification of specimens and examination with-
out knowing the clinical diagnosis (blinding); examination of all
specimens stained with one antibody under identical conditions
at one time; independent examination and scoring by two
experienced investigators; and photomicrography using stan-
dardized techniques.
The chi—square test was used to examine whether associa-
tions existed between the estimated pattern (peripheral vs.
mesangio-peripheral) of immunoglobulin (IgA, IgG, 1gM), fibro-
nectin or C3b/iC3b deposits on the one hand and MAC-related
antigens or other C-dependent antigens on the other hand.
The deposition pattern (m vs. mp) of IgA corresponded to
that of C3b/iC3b (P < 0.002). Similarly, the IgA pattern
corresponded to that of the MAC neoantigen (P < 0.01), of
properdin (P < 0.002) and that of C3d(P < 0.02); correspon-
dence of C3b/iC3b or properdin and MAC pattern was less
pronounced (P < 0.2 and P < 0.05, respectively). Correspon-
dence of C3d and MAC pattern was closer (P < 0.01). (Calcu-
lations were based on all cases in whom the respective staining
could be performed including both IgA-GN and HSP cases).
Deposition patterns of IgG or 1gM did not correspond to that
of any of the complement derived antigens.
The patterns of deposition of MAC-related antigens, that is,
C5, C6, C9 and MAC neoantigens, were uniform (either all
mesangial or all mesangio-peripheral) in 13 of 14 cases of
lgA-GN and HSP. The sum of the scores estimated for MAC-
related antigens, as defined above, correlated with histopathol-
ogy: IgA-GN specimens with MGL had lower (P = 0.05) scores
for MAC-related antigens than specimens with more advanced
non-sclerosing lesions (MGN, EEGN).
No significant correlation was detected between the sum of
the scores for MAC related antigens and serum creatinine or
hypertension. Proteinuria correlated with the sum of MAC
antigen scores (P < 0.01 for no proteinuria versus any degree of
proteinuria).
Discussion
Although in the past, many authors (2—5, 22—33) reported
deposition of C3 and some other complement (C) components
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Table 2. Continued
CS + C6
+ C9 +
Case MAC- MAC-neo
no. C3d B H P CS C6 C9 neo scored
IgA-glomerulonephritis
3+/rn 0 0 3+/rn 3+/rn 0 2+/rn 2+/rn 7
2 2+/rnp 0 1+/rn 2+/rn 2+/rn 0 1+/rn 2+/rn 5
3 3+/rnp 0 l+/rnp 1+/rn 1+/rnp l+/rnp 0 l+/rnp 3
4 3+/rnp 0 1+/rn 1+/rn NDC 2+/rn ND ND
5 3+/rnp 0 0 2+/rnp 2+/rnp 2+/mp 2+/mp 2+/rnp 8
6 3+/rn 2+/p 1+/rn 2+/rn 2+/rn 2+/rn 2+/rn 2+/rn 8
7 2+/rnp 0 0 1+/rn ND NDC ND NDC
8 2+/mp 0 0 2+/rn 2+/rnp 2+/rnp 2+/mp 2+/rnp 8
9 3+/rnp 0 0 2+/rn 3+/mp 2+/rnp 2+/mp 2+/rnp 9
10 3+/rnp NDC 0 1+/rn NDC 2+/rnp NDC NDC
II 3+/rnp 0 2+/rn 2+/rn 3+/rnp 2+/mp 2+/rnp 3+/mp 10
12 2+/rnp 0 0 1+/rn 1+/rn ND 1+/rn 1+/rn
13 3+/mp NDC 1+/rn 1+/rn 2+/rnp l+/mp NDC 2+/mp
14 3+/mp 0 1+/rn 2+/rnp 2+/rn 2+/mp 2+/rnp 2+/rnp 8
15 1+/rn 0 0 1+/rn 1+/rn 2+/rn 2+/rn NDC
16 2+/rn 0 0 2+/rn ND 2+/rn 2+/rn NDC
17 3+/rnp 0 0 2-f-/rnp 2+/rnp 2+/rnp I+/rnp 2+/rnp 7
18 3+/rnp 0 0 2+/rnp 2+/mp 2+/rnp I+/mp 2+/rnp 7
19 2+/rn 0 0 2+/rn 3+/rn 1+/rn 2+/rn 3+/rn 9
20 3+/rnp 0 0 2+/rn 2+/rn 2+/rn 2+/rn 2+/rn 8
21 3+/rn 0 0 1+/rn 2+/rn 2+/rn 1+/rn 2+/rn 7
22 3+/mp 0 l+/mp 1+/rnp 3+/rnp 2+/mp 3+/rnp 3+/mp II
23 3+/rn 0 0 0 3+/rn 1+/rn 2+/rn 2+/rn 8
Henoch—Schônlein purpura nephritis
24 3+/rnp 0 0 l+/rnp I+/rnp 2+/rnp 2+/rnp 2+/rnp 7
25 2+/rnp 0 0 1+/rnp I+/rnp 0 0 I+/rnp 2
Controls
26 NDC 0 0 0 0 0 0 0 0
27 2+/p 0 0 0 0 0 0 0 0
28 2+/p 0 0 0 0 0 0 0 0
29 3+/p 0 0 0 0 0 0 0 0
in the glomeruli of patients with IgA-GN or HSP, involvement
of the membrane attack complex (MAC) has not been demon-
strated to date in a larger series of patients with IgA-GN.
However, poly-9-neoantigen was noted in the glomeruli of some
(N = 3) patients IgA-GN and (N = 2) HSP in one study [34].
The present investigation gives immunohistological evidence
for consistent deposition of the terminal components of the
complement system (C5-9) in the mesangium and glomerular
capillaries of patients with lgA-GN and HSP. Evidence for
formation of such MAC is provided by the demonstration of
unique neoantigens. The neoantigen(s) is (are) not present on
the individual native components; they appear on several
components of C5-9 when the individual components undergo
complex formation and assemble to form the membrane attack
complex [13]. Neoantigens are incontroversial evidence of
formation of membrane attack complex. Deposition of MAC-
related antigens has previously been described for other forms
of human glomerulonephritis, such as membranous GN [35],
anti-basement membrane GN or Goodpasture's syndrome [35]
and SLE nephritis [36]. Direct [37] or indirect evidence for
functional involvement of the terminal complement compo-
nents has also been shown in experimental models of membra-
nous glomerulonephritis [38—42].
Several methodological problems must be considered before
our interpretation can be accepted that true neoantigens are
present and that this implies generation of—at least tran-
siently—active MAC activity. Falk et al [34] detected poly-
9-neoantigen, one component of MAC, not only in immunolog-
ically—mediated glomerular lesions, but also (apparently as a
result of antibody—independent complement deposition) in scar
tissue and non-immune renal lesions. In agreement with this
observation we detected granular and pseudo-linear (comma—
like) MAC deposits on the tubular basement membranes in 16 of
21 cases. Granular MAC deposits could furthermore be de-
tected in 16 of 21 cases intramurally in arterioles without
consistent IgA deposits in either site. However, co-localization
of extraglomerular MAC with C3d, that is, presence of both
early and terminal components, argues against an unspecific
deposition of preformed MAC at these sites.
Various tests for specificity, including immunoblotting (dot—
blot analysis with purified C5b-9: present study) and irn-
munoferritin staining [161 clearly demonstrated the high speci-
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Fig. 1. Extensive mesangial granular IgA deposits in JgA-GN (IF).
Note additional granular staining ( jmp-pattern") along the peripheral
capillary walls (arrowheads).
ficity of our antibody for MAC neoantigens and exclude cross-
reactivity with native complement components or other serum
proteins. The assumption that the majority of extracellular
MAC is present as SC5b-9 complex could be confirmed in
selected cases immunohistologically by staining with protein S
antibodies. Thus, immunohistological demonstration of MAC
neoantigens in the extracellular mesangial matrix does not
necessarily indicate presence of hemolytically active MAC;
however, extracellular presence of MAC implies with high
probability that adjacent cell membranes have been exposed to
hits of functionally active MAC at concentrations below the
detection threshold of the IF procedure.
Furthermore, demonstration of MAC neoantigens does not
necessarily indicate antibody—dependent complement activa-
tion; the possibility must also be considered that exposure to
protease activity in a glomerulonephritic mesangium might lead
to antibody—independent C-activation. This possibility is con-
sidered unlikely in the present study because MAC neoantigen
was uniquely co-deposited with IgA (and C3d) in the mesan-
gium and in the glomerular capillaries. The absence of MAC in
control glomeruli excludes non-specific post-biopsy in situ
complement activation.
The biological consequences of MAC deposition in the
mesangium are unknown. Using erythrocytes as target cells,
MAC has been well characterized as a cytolytic complex which
lyses cells by forming unique transmembrane channels which
lead to osmotic imbalance and lysis of target cells [43]. How-
ever, nucleated cells are markedly resistent to the lytic action of
MAC [44, 451. Consequently, mechanisms other than cytolysis
must be considered in the genesis of MAC-related tissue injury.
Additional or alternative possibilities include an indirect mod-
ulator role of MAC in the inflammatory process, such as a signal
[46] to release prostanoids (as recently demonstrated for mesan-
gial cells [47]) or cytokine(s). It has also recently been demon-
strated that MAC is internalized by nucleated cells [481; intra-
cellular presence of MAC opens a whole spectrum of potential
intracellular actions.
Variable mesangial MAC formation may explain the paradox-
ical observation [49] that there is little relation between the
Fig. 2. Mesungial deposits ('Sm "-pattern) of MAC as demonstrated by
polyclonal anti-MAC neoantigen antibodies (IF). Note the low back-
ground staining of Bowman capsule and of extraglomerular sites. The
arrowhead points to a MAC deposition in a peritubular capillary wall.
Fig. 3. Mesangio-peripheral pattern ("mp") ofMACneoantigens. The
arrow points to granular peripheral deposits in the capillary wall. Parts
of Bowmans capsule and (to a lesser degree) tubular basement mem-
brane show additional MAC deposits. Arrowheads indicate extensive
MAC deposition in a vessel wall.
amount of IgA deposited in the mesangium (as evaluated by
immunofluorescence) and evidence of mesangial cell injury, for
example phagocytosis, proliferation or mesangial matrix over-
production. Such discrepancy may be due to variable activation
of MAC by IgA deposits or variations of elimination half life. In
our study, despite presence of extensive IgA deposits on light
microscopy, patients who had only mild lesions by light micros-
copy had less MAC deposition than patients with more ad-
vanced non-scierosing lesions.
MAC-induced glomerular injury may not only concern
mesangial cells, but also capillary walls. It is of note that
involvement of glomerular capillaries by light microscopy or
immunofluorescence has been shown to be associated with
S.• a
S.
' 4"
S.
C.
/
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Fig. 5. Heavy mesangialfibronectin staining with partial pseudolinear
extensions into the peripheral capillaries (arrows) in IgA-GN.
Fig. 4. Upper part: IgA deposits in JgA-GN (IF); lower part: MAC
neoantigen pattern visualized in the same section as igA using AP-
labeled secondary antibodies and substrate reaction. Note co-localiza-
tion of the majority of deposits (except IgA-independent MAC deposi-
tion in Bowmans capsule membrane (arrows)).
more severe disease and more adverse prognosis of tgA-GN
[49, 501.
Experimental models of membranous GN [37—421 suggest
that a relation exists between deposition of MAC in glomerular
capillaries and appearance of proteinuria, either by irritation of
cells or by reducing the anionic sites in the glomerular basement
membrane [42]. Co-deposition of MAC and IgA in glomerular
capillary walls, as indicated by the present study, would be
compatible with the notion that MAC plays also a role in the
genesis of the prognostically more adverse capillary wall le-
sions.
The pattern of MAC deposition, that is mesangial or
mesangio-peripheral, corresponded to that of IgA deposition,
but not of IgG and 1gM deposition (the latter of which was
always less intense). This suggests that IgA aggregates or IgA
immunocomplexes are involved in the terminal activation of
complement components.
In the past, there has been much controversy whether IgA is
capable to activate the C-system. Activation of the alternative
pathway of complement in vitro by aggregated IgA and IgA-IC
has been found by some [51—56] but not all authors [57—59].
More recent observations, however, confirm C-activation by
IgA-IC: mouse myeloma IgA, forming immune complexes with
DNP-BSA, was shown to activate complement and to induce
local C-dependent lung injury in an Arthus—like rat model [60].
While evidence for C-activation by IgA-IC is incontroversial in
this model, we would like to caution, with respect to mesangial
IgA, that a role for the (unknown) antigen(s) or immunoglob-
ulins of other Ig-classes in the genesis of complement activation
has not been finally excluded.
With respect to the pathway involved, most authors [25, 33,
61] agree that—as also noted in this study—C3b and factor P are
frequently co-deposited with IgA in the absence of noticeable
Clq and C4. This suggests that in IgA-GN and HSP C-
activation occurs mainly or exclusively via the alternative
pathway. Deposits of C3d, and less consistently of C3b/iC3b,
corresponded topographically to those of MAC-neo. Resistance
of C3d against drastic conditions of elution suggests covalent
binding of C3d and strongly argues against non-specific binding.
The correspondence of C3d and MAC-neo patterns, such as
patterns of early and terminal C-components, is a strong
argument for complete local C-activation.
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